Cargando…
Deferasirox in a refractory anemia after other treatment options: case report and literature review
Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of...
Autor principal: | Manduzio, Palma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498843/ https://www.ncbi.nlm.nih.gov/pubmed/26185629 http://dx.doi.org/10.1002/ccr3.262 |
Ejemplares similares
-
Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature
por: Miyake, Zenshi, et al.
Publicado: (2020) -
Deferasirox: Duodenal perforation: case report
Publicado: (2021) -
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018) -
Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
por: Alqanatish, Jubran, et al.
Publicado: (2021) -
Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)